News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Seattle's Juno Therapeutics Pauses Trial After Patient Deaths


4/9/2014 7:07:21 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

One of the most exciting new avenues in cancer research is the development of techniques to genetically re-engineer a patient’s own immune cells to destroy tumors. Several companies are racing to commercialize this technology. In the lead are Novartis NVS +1.09%, working with researchers at the University of Pennsylvania, and Juno Therapeutics, a roll-up of research at Memorial Sloan-Kettering Cancer Center In New York and the Fred Hutchinson Cancer Research Center in Seattle that raised $145 million from investors including Jeff Bezos earlier this year. The team of Celgene CELG -0.65% and Bluebird has also entered the field, as has Kite Pharmaceuticals.

Help employers find you! Check out all the jobs and post your resume.

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES